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Objective To estimate prevalence of vaping in pregnancy.
Compare characteristics and attitudes between exclusive smokers
and vapers, and between exclusive vapers and dual users (smoke
and vape).
Design Cross-sectional survey.
Setting Hospitals across England and Scotland.
Population Pregnant women attending antenatal clinics in 2017.
Methods Women at 8–24 weeks’ gestation completed screening
questions about their smoking and vaping. Current or recent ex-
smokers and/or vapers completed a full detailed survey about
vaping and smoking.
Main outcome measures The prevalence of vaping, characteristics
and attitudes of women who vape and/or smoke.
Results Of 3360 pregnant women who completed screening
questions, 515 (15.3%, 95% CI 14.1–16.6) were exclusive smokers,
44 (1.3%, 95% CI 1.0–1.8) exclusive vapers and 118 (3.5%, 95% CI
2.9–4.2) dual users. In total, 867 (25.8%) women completed the full
survey; compared with smokers (n = 434), vapers (n = 140) were
more likely to hold higher educational qualifications (odds ratio
[OR) 1.51, 95% CI 1.01–2.25). Compared with exclusive vapers
(n = 33), dual users (n = 107) were younger (OR 0.91 95% CI
0.85–0.98) and less likely to hold high qualifications (OR 0.43, 95%
CI 0.20–0.96). Compared with smokers, dual users were more likely
to be planning to quit smoking (OR 2.27, 95% CI 1.24–4.18).
Compared with smokers, vapers were more likely to think vaping
was safer than smoking (78.6% versus 36.4%).
Conclusions One in 20 pregnant women report vaping, and most
also smoke. Dual users are more motivated towards stopping
smoking than smokers. Where women have tried but cannot stop
smoking, clinicians could encourage them to consider vaping for
smoking cessation.
Keywords E-cigarettes, pregnancy, prevalence, smoking, vaping.
Tweetable extract One in 20 women report vaping during
pregnancy but of those that do vape, most also smoke, despite
having intentions to quit.
Please cite this paper as: Bowker K, Lewis S, Phillips L, Orton S, Ussher M, Naughton F, Bauld L, Coleman T, Sinclair L, McRobbie H, Khan A, Cooper S.
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Introduction
Smoking when pregnant affects the health of women and
their fetus.1–4 Global prevalence of smoking in pregnancy is
around 2% but varies between countries and regions.5 In
England around 11% of women self-report smoking at the
time of delivery, with higher rates among women below
the age of 20 years and those in routine or manual
occupations.6,7 Most women who quit during pregnancy,
relapse within the first 6 months after birth.8–10
The prevalence of vaping outside of pregnancy is 5–7%11
and has remained stable in recent years.12–15 The most fre-
quently reported reason for vaping is to help quit smoking,
and ex-smokers often report vaping to prevent relapse.16 In
non-pregnant smokers, a large trial found electronic cigar-
ettes (ECs) to be more effective for cessation than nicotine
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replacement therapy (NRT).17 ECs are not risk-free; how-
ever, compared with smoking, ECs are likely to be less
harmful18; long-term vapers who do not smoke have lower
levels of carcinogens and toxins.19
There is limited information about the nature or extent
of EC use in pregnancy20–24 and few studies have addressed
the safety. ECs often contain nicotine and the effects of
using nicotine, particularly in higher doses, is unclear in
the human pregnancy.25Some studies indicate an associa-
tion between ECs and adverse infant outcomes26,27 and
dual use (smoking and vaping) is not associated with lower
nicotine intake.28 However, others have shown associations
between exclusive vaping (non-smokers) and higher birth-
weight compared with women who smoke during preg-
nancy.29 In addition, ECs do not expose users to toxic
products of combustion, which are associated with adverse
effects on the fetus.30A large trial in pregnancy is currently
assessing the effectiveness of ECs.31 UK advice for health
professional, is in favour of using ECs in pregnancy in
order to avoid smoking.32 Understanding who vapes during
pregnancy, how they vape and attitudes towards vaping will
help health professionals target and support pregnant
smokers to use ECs, who might otherwise continue to
smoke, and assist vapers who continue to smoke to stop
smoking.
We aimed to estimate the prevalence of vaping in preg-
nancy and compare characteristics, smoking behaviour and
attitudes of pregnant women who smoke exclusively (and
do not vape) with pregnant women who vape. For women
who reported currently vaping in pregnancy, we compared
the characteristics of exclusive vapers with dual users.
Methods
Study design
This paper reports cross-sectional baseline findings from a
UK longitudinal cohort study, designed to explore the use
of and attitudes towards EC during pregnancy. Anyone
over 16 years old and 8–24 weeks pregnant were eligible to
answer an initial set of short questions (screening survey)
which asked their vaping and smoking status; those who
were recent ex-smokers, currently smoked and/or vaped
were invited to complete a longer survey (the full survey).
Consent was then gained to complete a further two surveys
in late pregnancy and postpartum. We report findings from
the first survey here. Women were offered a £10 high street
shopping voucher for completing the full survey.
Recruitment of participants
We used purposive non-probability sampling by selecting
17 National Health Service (NHS) hospital recruitment
sites with varying smoking in pregnancy rates from a range
of geographical locations across the UK (England and
Scotland). We recruited from various antenatal clinics at
each hospital (e.g. general and specialist); between June
and November 2017 a research midwife/nurse systemati-
cally handed out a screening survey to all pregnant women
attending selected clinics.
The screening survey contained a question asking women
whether they had completed the survey before; if they had,
they were then excluded from answering any further ques-
tions. Each hospital was asked to recruit approximately 44
women into a longitudinal cohort. Women who completed
the full survey, were asked for their contact details and
given a unique identifier; a member of the research team
cross-matched these details to ensure each woman only
completed the full survey once.
Of 4193 pregnant women handed the screening survey,
3360 (80.0%) were eligible to complete the initial screening
questions about smoking and vaping; 797 women were
ineligible (20.0%) due to gestation (<8 weeks/>24 weeks)
or age (<16 years), or because they had completed the sur-
vey before (Figure S1).
This work was funded by Cancer Research UK, Tobacco
Advisory Group Project and was externally peer-reviewed
(Grant number C53479/A22733). A patient public involve-
ment panel (PPI) was involved in the study concept and
design. Table S1 shows in more detail how PPI was used in
this study. Ethical approval was given by the South West
Frenchay Research Ethics Committee. Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) guidance33 and Transparent Reporting of Evalu-
ations with Nonrandomized Designs (TREND)34 guidance
were used for reporting. Full details of the study are in the
protocol35 and Research Registry database.36
Survey content and measurements
The survey was divided into two parts: the screening survey
and the full survey (Appendix S1).
Screening survey
Women were asked their gestation (weeks pregnant), age
and whether they had completed the survey previously.
They were then asked about current smoking and vaping
status. For smoking, the categories were: never smoker, ex-
smoker (stopped smoking more than 3 months before
finding out they were pregnant), recent ex-smoker (stopped
smoking in the 3 months before pregnancy or after finding
out about pregnancy), and current smoker (smoke occa-
sionally, but not every day; smoke every day, but have cut
down; smoke every day, about the same as before preg-
nancy; smoke every day, more than before pregnancy). For
vaping, the categories were: never vaped (never heard of
EC and never tried; heard of EC but never tried), ex-vaper
(tried, but do not use now), current vaper (currently use
ECs, but not every day; use ECs every day).
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Full survey
In the full survey, participants were asked questions about
their views and experiences of using ECs, including a com-
bination of original questions and ones derived from previ-
ous studies (shown by citations). This included questions
about future intentions to use ECs in pregnancy and the
postpartum37 (answers on a 5-point Likert scale, ranging
from very likely to very unlikely). Attitudes towards and
acceptability of the use of ECs during pregnancy including
views on safety of use during pregnancy and vaping safety
compared with smoking and NRT38 (answers on a 7-point
Likert scale, ranging from strongly disagree to strongly
agree).
Participants were also asked questions about their cur-
rent smoking behaviour and beliefs: when they last smoked
(in the last 24 h, 1–6 days ago, 7–30 days ago, 1–2 months
ago, 2–3 months ago, more than 3 months ago), nicotine
dependence, which was categorised according to the Heavi-
ness of Smoking Index (HSI)39,40 (time to first smoking in
the morning and number of cigarettes per day), and atti-
tudes to stopping smoking in pregnancy, including when
they tried to stop smoking during pregnancy (yes/no/
stopped smoking before I became pregnant) and whether
they were planning to quit (yes, within next 2 weeks/yes,
within the next 30 days/yes, within the next 3 months/no).
Cigarettes smoked per day (CPD) were categorised as either
‘0–10’ or ‘≥11’ to distinguish between heavy and light
smokers41; we included zero, as some women smoked occa-
sionally but not every day.
Demographic questions asked about educational attain-
ment, age participant left education and ethnicity.
Measurements
The main outcome measure was smoking and vaping status
collected from the screening survey questions, and was
defined as follows.
‘Exclusive smokers’: pregnant women who reported they
currently smoked cigarettes (daily or occasionally) and were
not currently using an EC.
‘Vapers’: pregnant women who currently used an EC
(daily or occasionally); vapers were sub-divided into ‘exclu-
sive vapers’ who currently used an EC but did not cur-
rently smoke, and ‘dual users’ who currently used an EC
(daily or occasionally) and also currently smoked cigarettes
(daily or occasionally).
We excluded recent ex-smokers who were not using ECs
from our comparisons in our analysis as there is already
strong evidence to show that pregnant women who quit
smoking are systematically different from those who con-
tinue.42,43
Multiple choice and Likert type scales were collapsed
into smaller categories due to low use of some of the
response options. Questions that used yes/no responses
were not recategorised. Continuous data were not normally
distributed and were summarised into medians/interquar-
tile ranges.
Sample size
The sample size calculation was based on the precision of
estimates of prevalence of vaping and smoking for the lon-
gitudinal cohort study. We determined a priori that a sam-
ple size of 600 women would ensure adequate precision,
using a Wilson score 95% confidence interval for small
proportions and assuming the prevalence is around 5%, to
provide 95% confidence limits of 3.5–7%, with greater pre-
cision for estimates of prevalence for the baseline screening
survey. The actual precision for those that completed the
screening survey is apparent from the 95% confidence
intervals presented.
Data analysis
We used screening survey responses to estimate the preva-
lence of vaping and smoking for all pregnant women with
95% confidence intervals. We used estimates of the propor-
tions, in the following categories: exclusive smokers, exclu-
sive vapers and dual users. We then compared prevalence
of vaping and smoking status (smokers/non-smokers/exclu-
sive vapers, dual users) by age group, gestation when
recruited into the study and region using Chi-square tests.
For those who were eligible and completed the full sur-
vey, we described maternal characteristics, smoking and
vaping behaviour, and attitudes towards ECs among all
participants. Then we used these latter independent vari-
ables to conduct Chi-square tests to determine differences
between all women who vaped (both exclusive and dual
users) and those who were exclusive smokers, and any dif-
ferences between exclusive vapers and dual users. We used
the Mann-Whitney U-test to compare age between the
groups. We compared current smoking behaviour between
dual users and exclusive smokers using Chi-square tests.
Logistic regression was used to obtain the odds ratio (OR)
for any significant findings.
Missing data are described but were excluded from sig-
nificance tests. We did not use multiple imputation, as for
most variables less than 5% of responses were missing. The
P-values were deemed significant if they were less than
0.05. Analysis was carried using STATA-SE version 15 (Sta-
taCorp LLC, College Station, TX, USA).
Results
In all, 3360 women completed a screening survey; 2336
(69.5%) of the women had never smoked, had stopped
smoking >3 months ago and/or were not current vapers,
and therefore were not eligible to complete the full survey
(Figure S1). A total of 1024 (30.5%) reported they were a
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smoker, recent ex-smoker and/or vaped; 867 (25.8%) com-
pleted the full survey.
A total of 515 women (15.3%, 95% CI 14.1–16.6) who
completed the screening survey were exclusive smokers, 162
(4.8%, 95% CI 4.1–5.6) were currently vaping; 44 (1.3%,
95% CI 1.0–1.8) were exclusive vapers and 118 (3.5%, 95%
CI 2.9–4.2) were dual users (Table 1). Women were pre-
dominantly between the ages 25 and 34 years (57.6%),
from the North of England (27.1%) and in their second
trimester of pregnancy (50.6%). There were statistical dif-
ferences between vaping and smoking status by age group
and region in which the participant was recruited
(P ≤ 0.001) but not with gestation at recruitment.
Table S2 provides a detailed breakdown of self-reported
smoking and vaping of everyone who completed the
screening questions; one woman (0.03%) who had never
smoked reported being a current vaper.
Table 2 shows the characteristics of the 867 women who
completed the full survey (i.e. those who were current or
recent ex-smokers, and/or vapers). There were 434 (50.1%,
95% CI, 46.7–53.4) exclusive smokers and 140 (16.1%,
95% CI, 13.8–18.8) current vapers (dual and exclusive); of
the vapers, 33 (23.6%) were exclusive vapers and 107
(76.4%) were dual users. Educational level was a significant
predictor of EC use; having an educational attainment of
A-level or above compared with GCSE or less increased the
odds of using an EC by 51% (OR 1.51, 95% CI 1.01–2.25).
When comparing pregnant women who are exclusive
vapers with dual users, dual users were significantly
younger (OR 0.91, 95% CI 0.85–0.98), less likely to hold a
higher level of qualification (OR 0.43, 95% CI 0.20–0.96),
less likely to have stayed in education above the age of
16 years (OR 0.34, 95% CI 0.15–0.78), more likely to
report their pregnancy was unplanned (OR 3.74, 95% CI
1.65–8.50) and more likely to have smoked in previous
pregnancies (OR 4.04, 95% CI 1.59–10.29) (Table 2).
Table 3 describes smoking and vaping behaviour includ-
ing intention to quit for all those who completed the full
survey and compares exclusive smokers and vapers. Com-
pared with exclusive smokers, dual users were more likely
to be planning to quit smoking (OR 2.27, 95% CI 1.24–
4.18) and to report not smoking in the previous 24 h (OR
7.93, 95% CI 4.86–12.93). Over half of women who were
exclusive vapers (57.6%) had stopped smoking before preg-
nancy, and 74.8% of dual users and 70.3% of exclusive
smokers had tried to stop smoking after becoming preg-
nant.
Table 4 describes attitudes to EC use in pregnancy
among all those who completed the full survey and com-
pares exclusive smokers with vapers (exclusive and dual).
Vapers were more likely to think using an EC was safer
than smoking (78.6 versus 36.4%). There was no significant
difference in their perception of the harms of nicotine in
pregnancy, with most vapers (70%) and smokers (76%)
agreeing with the statement ‘nicotine is harmful to my
unborn baby’. There were no significant differences between
dual and exclusive vapers in their attitudes towards ECs or
how acceptable they found them (data not shown).



















Age (years) 16–24 794 (23.6) 3 (6.8) 203 (39.4) 45 (38.1) <0.001
25–34 1936 (57.6) 35 (79.6) 250 (48.5) 55 (46.6)
35≥ 604 (17.9) 6 (13.6) 62 (12.0) 16 (13.6)
Missing*** 26 (0.8) 0 0 2 (1.7)
NHS sites
by region
South 728 (21.7) 6 (0.8) 95 (13.0) 13 (1.8) <0.001
London 546 (16.3) 3 (0.5) 54 (9.9) 11 (2.0)
Midlands 859 (25.6) 22 (2.6) 194 (22.3) 39 (4.5)
North 909 (27.1) 10 (1.1) 138 (15.2) 38 (4.2)
Scotland 318 (9.5) 3 (0.9) 34 (10.7) 17 (5.3)
Gestation at
recruitment
1st trimester 1543 (45.9) 23 (52.3) 219 (42.5) 55 (46.6) 0.18
2nd trimester 1699 (50.6) 20 (45.5) 287 (55.7) 58 (49.2)
Unknown/Missing*** 118 (3.5) 1 (2.3) 9 (1.8) 5 (4.2)
*Percentages presented in columns for those who completed the screening questions in the survey.
**Percentages presented by rows for the breakdown by vaping and smoking status.
***Missing excluded from chi-square analysis.
****P-value to determine statistical differences between vaping and smoking status (smokers/non-smokers/exclusive vapers, dual users) by age
group, gestation when recruited into the study and region using Chi-square tests.
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Discussion
Main findings
This is the first UK study to report vaping prevalence, user
characteristics and attitudes towards vaping during preg-
nancy. Just under 5% of all pregnant women reported cur-
rently vaping, the majority of whom continued to smoke.
Among smokers and ex-smokers, just over 16% reported
vaping in pregnancy, mostly as dual users. Dual users were
more likely to report wanting to quit smoking and less
likely to have smoked in the previous 24 h compared with
exclusive smokers. There were significant differences
between dual users and exclusive vapers; dual users were
younger, less educated, less likely to have a planned preg-
nancy and more likely to have smoked in a previous preg-
nancy. Over half of exclusive vapers had stopped smoking
before becoming pregnant.
Strength and limitations
Strengths include the prospective recording of data during
pregnancy, rather than retrospective data collection post-
partum, reducing recall error and bias. The selection of
hospital recruitment sites was non-random, as we only
used hospitals that had research nurses/midwives available
to recruit, although the majority of hospitals in England
have this service available.44 Efforts were made to ensure a




























Age Median [IQR] 26 (22–31) 26 (23–31) 26 (22–31) 0.18 28 (26–33) 26 (22–29) 0.007






502 (57.9%) 84 (60.0%) 296 (68.2%) 0.04 15 (45.5.0%) 69 (64.5%) 0.04
A levels/degree,
similar or above**
348 (40.1) 54 (38.6%) 126 (29.0%) 18 (54.6%) 636 (33.6%)
Missing* 17 (2.0%) 2 (1.4%) 12 (2.8%) 0 (0%) 2 (1.9%)
Age left
education
≤16 415 (47.9%) 73 (52.1%) 251 (57.8%) 0.61 11 (33.3%) 62 (57.9%) 0.03
≥17 408 (47.1%) 58 (41.4%) 161 (37.1%) 20 (60.6%) 38 (35.5%)
Still in education 25 (2.9%) 5 (3.6%) 10 (2.3%) 1 (3.0%) 4 (3.7%)
Missing* 19 (2.2%) 4 (2.9%) 12 (2.8%) 1 (3.0%) 3 (2.8%)
Ethnicity White British 759 (87.5%) 131 (93.6%) 382 (88.2%) 0.53 31 (93.9%) 100 (93.5.2%) 0.76
Other 63 (11.1%) 7 (5.0%) 45 (10.4%) 2 (6.1%) 5 (4.7%)
Missing* 12 (1.4%) 2 (1.4%) 7 (1.6%) 0 (0%) 2 (1.9%)
Gestation at
recruitment
1st trimester 399 (46.0%) 72 (51.4) 188 (43.3) 0.06 21 (63.6) 51 (47.7) 0.91
2nd trimester 460 (53.1) 65 (46.4) 243 (56.0) 11 (33.3) 54 (50.5)
Don’t know/missing 8 (0.9) 3 (2.1) 3 (0.7) 1 (3.0) 2 (1.9)
Previous
pregnancy
Yes 561 (64.7%) 100 (71.4%) 306 (70.5%) 0.50 27 (81.8%) 73 (68.2%) 0.27
No 288 (33.2%) 34 (24.3%) 121 (27.9%) 6 (18.2%) 28 (26.2%)
Missing* 18 (2.1%) 6 (4.3%) 7 (1.6%) 0 (0%) 6 (5.6%)
If yes – smoked
in previous
pregnancy
Yes 345 (61.5%) 72 (72.0%) 232 (75.8%) 0.32 13 (48.2%) 59 (80.8%) 0.007
No 197 (35.1%) 26 (26.0%) 59 (19.3%) 14 (51.9%) 12 (16.4%)
Don’t remember 12 (2.1%) 2 (2.0%) 8 (2.6%) 0 (0%) 2 (2.7%)
Missing* 7 (1.3%) 0(0%) 7 (2.3%) 0(0%) 0 (0%)
Planned
pregnancy
Yes 292 (33.7%) 43 (30.7%) 121 (27.9%) 0.53 18 (54.6%) 25 (23.4%) 0.001
No 548 (63.2%) 93 (66.4%) 299 (68.9%) 15 (45.4%) 78 (72.9%)
Missing* 27 (3.1%) 4 (2.9%) 14 (3.2%) (0%) 4 (3.7%)
*Missing data excluded from chi-square analysis. 6¼ P-values are for comparisons between exclusive smokers (who do not vape) and dual users.
**GCSE: General Certificate of Secondary Education, compulsory exams in the UK taken at age 15–16. A levels: General Certificate of Education
Advanced Level certificate, non-compulsory exams, taken in the UK, after compulsory education ends. To note: The remaining 293/867 women
who completed the full survey were recent ex-smokers who were not using e-cigarettes and are not included in table.
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wide range of geographical locations, socio-economic areas
and variation in smoking in pregnancy rates. Non-smokers
may have been less likely to complete the screening survey
as they might consider the topic not relevant and non-Eng-
lish readers would not be included. We did not record how
many declined to complete the screening survey; however,
in a previous study measuring smoking prevalence in
pregnancy, using very similar methods, the rate of decline
was only 4.5%.42 The socio-demographic profile of the
smokers was similar to previous cohort studies measuring
smoking in pregnancy; women were predominantly white-
British, with low education.6,42,45 Only women who
attended antenatal clinics were surveyed; however, most
women in the UK attend these appointments.46






























Yes 639 (73.7%) 94 (67.1%) 305 (70.3%) 0.28 14 (42.4%) 80 (74.8%) <0.001




61 (7.0%) 19 13.6% 0% 19 (57.6%) 0 (0%)






Likely 199 (23.0%) 103 (73.6%) 82 (18.9%) <0.001 24 (72.7%) 79 (73.8%) 0.02
Neither likely
or unlikely
113 (13.0%) 16 (11.4%) 79 (18.2%) 3 (9.1%) 13 (12.2%)
Unlikely 432 (49.8%) 8 (5.7%) 188 (43.3%) 5 (15.2%) 3 (2.8%)
I don’t know 94 (10.8%) 10 (7.1%) 68 (15.7%) 1 (3.0%) 9 (8.4%)
Missing* 29 (3.3%) 3 (2.1%) 17 (3.9%) 0 3 (2.8%)




Likely 212 (24.5%) 91 (65.0%) 98 (22.6%) <0.001 22 (64.5%) 69 (64.5%) 0.78
Neither likely
or unlikely
138 (15.9%) 26 (18.6%) 79 (18.2%) 6 (18.2%) 20 (19.0%)
Unlikely 381 (43.9%) 6 (4.3%) 168 (38.7%) 1 (3.0%) 5 (4.7%)
I don’t know 107 (12.3%) 13 (9.3%) 70 (16.1%) 4 (12.1%) 9 (8.4%)
Missing* 29 (3.3%) 4 (2.9%) 19 (4.4%) 0 4 (3.7%)
Current smokers
only
541 -- 434 NA 107 <0.001 6¼
Last smoked ≤24 h 470 (86.9%) -- 390 (89.9%) 80 (74.8%)
>24 h 59 (10.9%) -- 34 (7.8%) 25 (23.4%)










158 (29.2%) -- 131 (30.2%) 27 (25.2%)




0–10 387 (71.5%) -- 306 (71.0%) 81 (75.7%)
≥11 128 23.7%) -- 110 (25.4%) 18 (16.8%) 0.09 6¼





Yes 362 (66.9%) -- 286 (65.9%) 76 (71.0%) 0.01 6¼
No 128 (23.7%) -- 114 (26.3%) 14 (13.1%)
Missing* 52 (9.4%) -- 34 (7.8%) 17 (15.9%)
Note:The remaining 293/867 women who completed the full survey were recent ex-smokers who were not using e-cigarettes.
*Missing data excluded from chi-square analysis. 6¼ P-values are for comparisons between exclusive smokers (who do not vape) and dual users.
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Reliance on self-reported smoking and vaping status may
lead to under-reporting.47 The social stigma of smoking is
well known and qualitative work suggests there is also a
stigma associated with vaping;37 however, the surveys were
anonymous, everyone was asked to complete them, and
this could be done quickly and discreetly. We did not
report whether women were using other forms of nicotine
in pregnancy, such as NRT; however, this is generally
low.48 Another caution is that the number of vapers, par-
ticularly exclusive vapers, is relatively low, and a quarter of
reported exclusive vapers from the screening survey did not
complete the full survey. Therefore, findings may not be
representative of all pregnant vapers and we may have
missed small differences between exclusive vapers and dual
users. Also, as countries vary in smoking prevalence5 it is
likely vaping prevalence will, too, therefore these results
Table 4. Attitudes towards e-cigarette (EC) use in pregnancy; comparisons between pregnant vapers and exclusive smokers











exclusive smokersn = 867 n = 140 (16.1%) n = 434 (50.1%)




Agree 483 (55.7%) 117 (83.6%) 235 (54.2%) <0.001
Neither agree or disagree 165 (19.0%) 16 (11.4%) 94 (21.7%)
Disagree 208 (24.0%) 6 (4.3%) 99 (22.8%)
Missing* 11 (1.3%) 1 (0.7%) 6 (1.4%)
Vaping in pregnancy
harms my baby
Agree 294 (33.9%) 11 (7.9%) 126 (29.0%) <0.001
Neither agree or disagree 448 (51.7%) 87 (62.1%) 246 (56.7%)
Disagree 114 (13.2%) 41 (29.3%) 56 (12.9%)
Missing* 11 (1.3%) 1 (0.7%) 6 (1.4%)
Vaping in pregnancy
is as safe as using
nicotine patches
Agree 151 (17.4%) 43 (30.7%) 68 (15.7%) <0.001
Neither agree or disagree 492 (56.8%) 76 (54.3%) 249 (57.37%)
Disagree 214 (24.7%) 19 (13.6%) 113 (26.0%)
Missing* 10 (1.2%) 2 (1.4%) 4 (0.9%)
Vaping in pregnancy
is much less harmful
than tobacco
cigarettes
Agree 415 (47.9%) 110 (78.6%) 158 (36.4%) <0.001
Neither agree or disagree 304 (35.1%) 24 (17.1%) 189 (43.6%)
Disagree 135 (15.6%) 4 (2.9%) 80 (18.4%)
Missing* 13 (2.0%) 2 (1.4%) 7 (1.6%)
Nicotine is harmful to
my unborn baby
Agree 674 (77.7%) 98 (70.0%) 330 (76.0%) 0.19
Neither agree or disagree 140 (16.2%) 29 (20.7%) 80 (18.4%)
Disagree 42 (4.8%) 11 (7.9%) 19 (4.4%)
Missing* 11 (1.3%) 2 (1.4%) 5 (1.2%)
Most important
reasons for vaping in
pregnancy*
To help quit smoking 392 (45.2%) 65 (46.4%) 184 (42.4%) 0.06
To help cut down cigarettes 40 (4.6%) 6 (4.3%) 25 (5.8%)
Less harmful to others around me
compared to tobacco smoke
28 (3.2%) 0 (0%) 12 (2.8%)
Healthier than tobacco cigarettes 26 (3.0%) 5 (3.6%) 10 (2.3%)
They are cheaper than
tobacco cigarettes
13 (1.5%) 1 (0.7%) 6 (1.4%)
Other 53 (6.1%) 2 (1.4%) 27 (6.2%)





They do not get rid of the
smoking habit
102 (11.8%) 12 (8.6%) 49 (11.3%) 0.009
Not enough research 135 (15.6%) 21 (15.0%) 52 (12.0%)
Bad stories in press/ social media 81 (9.3%) 9 (6.4%) 59 (13.6%)
Worried about side effects 71 (8.2%) 7 (5.0%) 25 (5.8%)
Do not get rid of nicotine addiction 52 (6.0%) 15 (10.7%) 17 (3.9%)
Other 154 (17.8%) 49 (35.0%) 89 (20.5%)
Missing* 272 (31.4%) 49 (35.0%) 143 (33.0%)
Note:The remaining 293/867 women who completed the full survey were recent ex-smokers who were not using e-cigarettes.
*Missing data excluded from chi-square analysis *There were multiple answers to the questions asked about the most important reason to use or
not to vape: the five most commonly reported answers are presented in the tables.
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may not apply to all pregnant populations. Women below
the age of 16 years were excluded, therefore we do not
report vaping patterns in this age category. Data collected
about attitudes and beliefs should be approached with cau-
tion, as responses will be limited to the questions asked;
further qualitative research is required to establish the
validity of responses.
Interpretation
Previous studies, mostly based in the USA between 2014
and 2017, estimated the prevalence of vaping during preg-
nancy to be 0.6–15%.20–23,49 Variations in findings are
likely due to different data collection and recall periods,
including use before or at differing points during preg-
nancy. Our findings show that 4.8% of pregnant women
are vaping in early pregnancy. Previous UK data from Stop
Smoking Services (SSS), a free support service in the UK,
found only 2.2% women were vaping in pregnancy (16);
however, this figure will not include those who quit smok-
ing before or on discovering they are pregnant. Our find-
ings suggest that one in 20 pregnant women in England
and Scotland whom antenatal clinicians encounter is vap-
ing. Among pregnant smokers or ex-smokers, around 16%
are vaping, which is far greater than that reported by SSS,
as many pregnant smokers do not access these services.
Understanding the characteristics of pregnant vapers and
reasons women vape is clearly relevant to antenatal care,
and clinicians require knowledge and skills to deal appro-
priately with issues arising from this.
Around three-quarters of vapers were dual users, which
concurs with findings showing that both pregnant20,22 and
non-pregnant vapers15 often continue to smoke. Outside of
pregnancy, dual users report that vaping is a way to reduce
their smoking below a perceived harm threshold.50 Reduced
levels of carbon monoxide have been identified in non-preg-
nant dual users who significantly cut down their smoking.51
However, the greatest reduction in toxicant exposure is seen
in EC users who completely stop smoking.19,28 Understand-
ing how clinicians can support pregnant vapers to stop
smoking is required; our finding that, like other women who
smoke during pregnancy,6,42 dual users were younger and
less likely to hold higher educational qualifications compared
with exclusive vapers could help target behavioural cessation
support by addressing social influences, knowledge and
intentions in these specific groups.
Over half of exclusive vapers in our study reported stop-
ping smoking before pregnancy. Outside of pregnancy, vap-
ing among long-term ex-smokers is common,15,17 and in
one randomised controlled trial (RCT) 80% of those absti-
nent after 1 year and assigned to ECs reported still using
them.17 Understanding pregnant women’s reasons for con-
tinued use would help provide more appropriate support
for women who want to quit both vaping and smoking.
A majority of vapers believed ECs were safer than smok-
ing during pregnancy, and this did not differ between dual
and exclusive vapers, therefore facilitating beliefs may be
important in the uptake of vaping. However, both vapers
and smokers were undecided about the harms of using
nicotine during pregnancy. Animal studies have shown that
nicotine is associated with detrimental neurological and
behavioural effects on the fetus.25,52 The effects of high-
dose nicotine alone in human pregnancy is unclear.25 How-
ever, the short-term53,54 and long-term effects of nicotine
exposure through NRT in human pregnancy are not associ-
ated with greater risk to the fetus55 or infant.56 Perinatal
exposure to ECs in animals23 is potentially detrimental and
there are mixed reviews about their safety in human stud-
ies,26–29 but data are very limited. However, similar to
NRT, ECs have no products of combustion and this may
prevent most tobacco-related harms30 if successfully used
to quit. For women to make informed decisions about
using ECs to stop smoking, clinicians and healthcare provi-
ders should supply women with the latest evidence.
Conclusion
Our findings suggest that in England and Scotland, one in 20
women use e-cigarettes in pregnancy, most of whom smoke
concurrently. Among women who smoke in pregnancy or did
so shortly before conception, around 16% are vaping. Cur-
rently, the UK NHS supports pregnant smokers to stop smok-
ing; our findings show that clinicians need to be aware of the
frequency with which they are likely to encounter pregnant
women who vape. Pregnant dual users are more motivated
towards stopping smoking than are women who only smoke.
Clinicians may consider encouraging smokers who have
unsuccessfully tried stopping, to consider vaping as a step
towards stopping smoking; understanding the characteristics
of pregnant vapers and reasons for vaping may help with this.
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